FRANKFURT May 6 German diversified healthcare
group Fresenius said on Tuesday it was not preparing
any major deals to bolster its medical nutrition and generic
drugs unit Kabi.
"All M&A projects Kabi is currently working on are small to
medium-sized in nature. We are not pursuing any large
transactions in the billion-euro-plus category at the present
time," Fresenius Chief Executive Ulf Schneider told analysts in
a conference call on Tuesday.
Sources told Reuters last month that the field of bidders
for Danone's Medical Nutrition business, valued at
about 4 billion euros ($5.6 billion), narrowed to Fresenius and
Swiss food company Nestle.
Financial sources have recently said, however, that the
talks have stalled, partly because of antitrust issues.
($1 = 0.7205 Euros)
(Reporting by Andreas Kroener; Writing by Ludwig Burger;
Editing by Marilyn Gerlach)